Gareth Macdonald
October 25, 2019
3 Min Read
![Gene therapy demand drives Cytovance pDNA expansion Gene therapy demand drives Cytovance pDNA expansion](https://eu-images.contentstack.com/v3/assets/blt0a48a1f3edca9eb0/blt6df46c4649408cb9/658aec2f6134db040a2c74e3/gene-therapy-Ankabala.jpg?width=1280&auto=webp&quality=95&format=jpg&disable=upscale)
Image: iStock/Ankabala
Cytovance Biologics has added plasmid DNA (pDNA) production capacity at its Oklahoma City facility citing growing demand from gene therapy developers.
The single-use production system is capable of making both critical reagent grade – for research – and cGMP grade pDNA in quantities ranging from 1g to 50g. It can manufacture smaller quantities for R&D.
Jesse McCool, Cytovance chief technology officer (CTO), framed the investment as part of the firm’s effort to position itself as a key gene therapy supply chain partner.
Image: iStock/Ankabala